Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):

	Year Ended December 31,
Net sales	2019		2018		2017
MedSurg	$	3,307	$	3,007	$	2,742
Rhythm and Neuro	3,140		3,041		2,808
Cardiovascular	4,208		3,777		3,500
Total net sales of reportable segments	10,654		9,823		9,048
All other (Specialty Pharmaceuticals)	81		n/a		n/a
Consolidated net sales	$	10,735	$	9,823	$	9,048

Reconciliation of depreciation by reportable segment to total [Table Text Block]

	Year Ended December 31,
Depreciation expense	2019		2018		2017
MedSurg	$	75	$	72	$	68
Rhythm and Neuro	92		91		91
Cardiovascular	138		133		120
Total depreciation expense of reportable segments	306		296		279
All other (Specialty Pharmaceuticals)	6		n/a		n/a
Consolidated depreciation expense	$	311	$	296	$	279

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

	Year Ended December 31,
Income (loss) before income taxes	2019			2018			2017
MedSurg	$	1,204		$	1,102		$	984
Rhythm and Neuro	666			655			537
Cardiovascular	1,137			1,117			988
Total operating income of reportable segments	3,007			2,875			2,509
All other (Specialty Pharmaceuticals)	56			n/a			n/a
Unallocated amounts:
Corporate expenses, including hedging activities	(264		)	(372		)	(252		)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs	(582		)	(398		)	(407		)
Amortization expense	(699		)	(599		)	(565		)
Operating income (loss)	1,518			1,506			1,285
Other expense, net	(831		)	(85		)	(353		)
Income (loss) before income taxes	$	687		$	1,422		$	933

Segment operating income as percentage of net sales [Table Text Block]

Operating income of reportable segments as a percentage of net sales of reportable segments	Year Ended December 31,
	2019		2018		2017
MedSurg	36.4	%	36.7	%	35.9	%
Rhythm and Neuro	21.2	%	21.5	%	19.1	%
Cardiovascular	27.0	%	29.6	%	28.2	%

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

	As of December 31,
Total assets	2019		2018
MedSurg	$	1,803	$	1,846
Rhythm and Neuro	1,873		1,696
Cardiovascular	2,535		1,954
Total assets of reportable segments	6,211		5,497
All other (Specialty Pharmaceuticals)	211		—
Goodwill	10,176		7,911
Other intangible assets, net	7,886		6,372
All other corporate assets	6,082		1,219
	$	30,565	$	20,999

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]

	As of December 31,
Long-lived assets	2019		2018		2017
U.S.	$	1,148	$	1,061	$	1,065
Ireland	327		242		210
Other countries	604		478		422
Property, plant and equipment, net	2,079		1,782		1,697
Goodwill	10,176		7,911		6,998
Other intangible assets, net	7,886		6,372		5,837
Operating lease right-of-use assets in Other long-term assets	336		—		—
	$	20,477	$	16,064	$	14,531